(Q36264494)

13 August 2017

1 reference

title

The antimicrobial armamentarium: evaluating current and future treatment options (English)

1 reference

13 August 2017

John A Bosso

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

25

1 reference

13 August 2017

issue

10 Pt 2

1 reference

13 August 2017

page(s)

55S-62S

1 reference

Trends in antimicrobial drug development: implications for the future

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

The macrolide binding site on the bacterial ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Fluorescence assay for studying the ability of macrolides to induce production of ribosomal methylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Functional analysis of the lipoglycodepsipeptide antibiotic ramoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.10PART2.55S

10.1592/PHCO.2005.25.10PART2.55S

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference